Eruptive lentiginosis confined to areas of regressing psoriatic plaques after adalimumab treatment

García‐Souto, Fernando

doi:10.1016/j.abd.2020.05.011

Cited by 4 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since then, several publications have expanded the phenomenon of eruptive lentiginosis at sites of resolving psoriatic disease to include patients receiving biologic therapies, including inhibitors of TNF-alpha (adalimumab [14,15 ▪ ], etanercept [16–18], infliximab [19,20]), IL-12 and IL-23 (ustekinumab [21], guselkumab [22]), as well as PDE-4 (apremilast [23,24]) and methotrexate [25]). Although some of the patients had received other immunosuppressive systemic therapies, such as cyclosporine, the temporal association of the onset of ILIAD in these cases strongly suggested a role for these biologics in triggering or accelerating the onset of the phenomenon.…”

Section: Psoriasismentioning

confidence: 99%

Odyssey toward an understanding of acquired postinflammatory lentiginosis

Yan¹

2021

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of review Acquired postinflammatory lentiginosis is a phenomenon that has been previously termed ‘induction of lentiginosis in assorted dermatoses’ or the ILIAD phenomenon. Recent findings Although some cases have been described as arising exclusively in those who applied topical calcineurin inhibitors (TCIs), other patients have presented with similar findings in other nonatopic disorders (contact dermatitis, psoriasis, lichen planus, focal dermal hypoplasia), and without antecedent use of TCIs. Summary Inflammatory skin disorders can produce localized areas of cutaneous lentiginosis, particularly as the inflammation retreats in response to treatment. This post-inflammatory lentiginosis or ILIAD phenomenon may be potentiated by use of topical and systemic anti-inflammatory medications, including TCIs, topical corticosteroids, methotrexate, and systemic biologic agents. Although this phenomenon has not been associated with melanocytic neoplasia, ongoing periodic monitoring for dysplastic changes is reasonable.

show abstract

Section: Psoriasismentioning

confidence: 99%

Odyssey toward an understanding of acquired postinflammatory lentiginosis

Yan¹

2021

Current Opinion in Pediatrics

View full text Add to dashboard Cite

show abstract

Hyperpigmentation with Café-au-Lait Spots or Lentigines

Tan

Zhu

2023

Atlas of Pigmentary Skin Disorders

View full text Add to dashboard Cite

Persistent eruptive lentiginosis in a psoriatic patient after 4‐year effective treatment with ustekinumab

Parietti

Burzi

Ribero

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

We herein report the case of a 48-year-old man with Fitzpatrick skin type II who has been affected by psoriasis since the adolescence. He was treated with topical products until he started therapy with methotrexate at the age of 39. Both therapies were not able to achieve successful results. He arrived at our attention at the age of 44 with a progressive worsening of the psoriasis with diffuse erythematous desquamative plaques on the trunk and F I G U R E 1 Clinical manifestation of eruptive lentiginosis in previous sites of psoriatic plaques on the back (A), abdomen (B), thigh (C) with dermoscopic pattern referable to lentigo (D) Michele Parietti and Lorenza Burzi share first authorship.

show abstract

Eruptive lentiginosis confined to areas of regressing psoriatic plaques after adalimumab treatment

Cited by 4 publications

References 4 publications

Odyssey toward an understanding of acquired postinflammatory lentiginosis

Odyssey toward an understanding of acquired postinflammatory lentiginosis

Hyperpigmentation with Café-au-Lait Spots or Lentigines

Persistent eruptive lentiginosis in a psoriatic patient after 4‐year effective treatment with ustekinumab

Contact Info

Product

Resources

About